ArticleLife (Basel, Switzerland)2024
Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.International journal of molecular sciences · 2026Review
- Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration-A Narrative Review.Biomedicines · 2026Review
- Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.Frontiers in immunology · 2026Review
- The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation.Frontiers in pharmacology · 2026Review
- Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon-Like Peptide-1 Receptor Agonists.Cardiovascular therapeutics · 2026Review
- GLP-1 receptor agonists alleviate inflammatory responses and endothelial dysfunction in atherosclerosis by activating the Sema3A/NRP1 pathway.Frontiers in cardiovascular medicine · 2026Article
- Role of glucagon-like peptide-1 receptor agonists in type 2 diabetes-associated atherosclerosis: from vascular mechanism to omics-based biomarkers and imaging.Frontiers in cardiovascular medicine · 2026Review
- Chronic Coronary Artery Disease: Wall Disease vs. Lumenopathy.Biomolecules · 2025Review
- Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection.Frontiers in medicine · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cardiovascular disease (CVD) remains a prominent cause of global mortality, primarily driven by atherosclerosis. Diabetes mellitus, as a modifiable risk factor, significantly contributes to atherogenesis. Monocyte recruitment to the intima is a critical step in atherosclerotic plaque formation, involving chemokines and adhesion molecules such as selectins, ICAM-1, and MCP-1. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a promising group of drugs for reducing cardiovascular risk in diabetic patients, prompting investigation into their mechanisms of action. This interventional study enrolled 50 diabetes patients with atherosclerotic plaque, administering GLP-1RA for 180 days. Serum concentrations of MCP-1, ICAM-1, and L-selectin were measured before and after treatment. Anthropometric and biochemical parameters were also assessed. GLP-1RA treatment resulted in significant improvements in anthropometric parameters, glycemic control, blood pressure, and biochemical markers of liver steatosis. Biomarker laboratory analysis revealed higher baseline levels of MCP-1, ICAM-1, and L-selectin in diabetic patients with atherosclerotic plaque compared to healthy controls. Following treatment, MCP-1 and L-selectin levels decreased significantly (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.